Every Form 4 that InfuSystem Holdings, Inc. (INFU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INFU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INFU filings page.
InfuSystem Holdings, Inc (INFU) reported a Form 4 for director Scott Shuda reflecting an indirect disposition of 20,000 shares of Common Stock on September 10, 2026, classified as an "other" non-cash transaction. The shares were distributed by Meridian OHC Partners, LP to one limited partner, and are held through entities over which Mr. Shuda has voting and dispositive power but for which he disclaims beneficial ownership for Rule 13d-3 purposes. After this transaction, 278,383 shares are reported as indirectly held and 94,000 shares as directly held. No trades are reported under a Rule 10b5-1 plan.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,323 performance-based restricted stock units granted on May 17, 2024 vested and converted into common shares, increasing his holdings.
Across May 16–18, 2026, Steele exercised restricted stock units covering 7,511 and 8,715 shares of common stock and had 3,275, 9,297 and 3,800 shares withheld to satisfy tax liabilities tied to these vestings. Following these transactions, he directly owned 117,767 shares of InfuSystem common stock. Certain remaining restricted stock units are scheduled to vest in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings EVP-Chief HR Officer Jerod Funke reported compensation-related stock activity involving restricted stock units and associated tax withholding. On May 17, 2026, 14,570 performance-based restricted stock units granted on May 17, 2024 vested and converted into common stock on a one-for-one basis.
To cover tax liabilities from vesting and settlement on May 16–17, 2026, a total of 8,761 shares of common stock were withheld at $8.77 per share, which is reported as a disposition but is not an open-market sale. Funke’s direct common stock holdings increased to 36,116 shares after these transactions, and 10,363 restricted stock units remain outstanding, vesting in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings President and CEO Carrie Lachance reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,855 performance-based restricted stock units granted on May 17, 2024 vested, converting into common stock on a one-for-one basis. On May 16 and May 18, she exercised restricted stock units covering 10,418 and 8,932 shares of common stock, respectively.
To cover tax liabilities from these vesting and settlement events, the issuer withheld 4,100 shares at $8.77, 5,322 shares at $8.77, and 3,515 shares at $8.90 per share. Following these transactions, Lachance directly holds 266,391 shares of common stock. Footnotes state that certain restricted stock units cliff vested on May 18, 2026, while others vest in two equal annual installments beginning May 17, 2027.
InfuSystem Holdings Executive VP and CIO Addam Chupa reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 16, 2026, 4,375 restricted stock units converted into common stock on a one-for-one basis, with 1,602 shares withheld at $8.77 per share to cover tax liabilities. On May 17, 2026, 12,184 performance-based restricted stock units granted on May 17, 2024 vested, and 4,460 shares were withheld at $8.77 per share for taxes. On May 18, 2026, an additional 5,447 restricted stock units cliff vested and converted into common stock, with 1,994 shares withheld at $8.90 per share for tax obligations. Following these non-market transactions, Chupa directly held 61,160 shares of InfuSystem common stock.
InfuSystem Holdings director Ronald T. Hundzinski received a stock option grant covering 24,890 shares of common stock. The option has an exercise price of $8.37 per share, vests on May 12, 2027, and expires on May 12, 2036. It represents a compensation-related award rather than an open-market purchase or sale. Following the reported transactions, Hundzinski holds 5,000 shares of InfuSystem common stock directly.
InfuSystem Holdings director Scott Shuda received a new stock option grant and reported his share holdings. He was granted options for 24,890 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036. The option represents the right to buy 24,890 shares and vests on May 12, 2027.
After these updates, Shuda holds 94,000 shares of common stock directly and 298,383 shares indirectly through Meridian OHC Partners, LP and BlueLine Capital Partners II, over which he has voting and dispositive power. He disclaims beneficial ownership of the shares held by Meridian and BlueLine for purposes of Rule 13d-3.
InfuSystem Holdings, Inc. director John J. Sviokla reported an equity compensation grant and his current shareholdings. He received stock options covering 24,890 shares of common stock at an exercise price of $8.37 per share. These options vest on May 12, 2027 and expire on May 12, 2036, giving him the right to buy shares in the future if conditions are met. The filing also shows he directly holds 10,000 shares of InfuSystem common stock following these transactions.
InfuSystem Holdings, Inc executive vice president and CIO Addam Chupa reported updated holdings and new equity awards. He now directly holds 47,210 shares of common stock, which the footnotes state includes 2,254 shares recently acquired through the company’s Employee Stock Purchase Plan.
On the same date, he received 9,973 restricted stock units that each convert into one share of common stock and 20,777 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the restricted stock units vest in three equal annual installments beginning on the same date.
InfuSystem Holdings director Beverly A. Huss reported an equity compensation grant. She received a stock option for 24,890 shares of common stock, with an exercise price of $8.37 per share. The option vests on May 12, 2027 and expires on May 12, 2036.
Following this grant, Huss holds 4,300 shares of common stock directly, along with the newly awarded options for 24,890 underlying shares. The filing reflects a compensation-related award rather than an open-market purchase or sale.
InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation. He was granted options to acquire 24,890 shares of common stock at an exercise price of $8.37 per share, expiring in 2036. These options vest on May 12, 2027. Following the reported transactions, he directly holds 70,000 shares of InfuSystem common stock, indicating this filing reflects equity-based incentives rather than open-market buying or selling.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported new equity awards. He received 17,121 restricted stock units that convert into common stock on a one-for-one basis and 35,668 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the RSUs vest in three equal annual installments starting the same date. After these awards, he directly holds 96,590 shares of common stock.
InfuSystem Holdings President and CEO Carrie Lachance reported new equity awards and updated holdings. She received a grant of 29,816 restricted stock units, which convert into common stock on a one-for-one basis and vest in three equal annual installments beginning on May 12, 2027. She also received a stock option covering 62,117 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036, vesting in four equal annual installments starting May 12, 2027. Following these awards, she directly holds 238,123 shares of InfuSystem common stock. These actions reflect compensation-related grants rather than open-market purchases or sales.
InfuSystem Holdings, Inc executive Jerod Funke, EVP–Chief HR Officer, reported new equity compensation awards. He received 11,478 restricted stock units, which each convert into one share of common stock and vest in three equal annual installments beginning on May 12, 2027.
He was also granted a stock option for 23,913 shares of common stock at an exercise price of $8.37 per share, vesting in four equal annual installments beginning May 12, 2027 and expiring on May 12, 2036. Following these awards, he holds 18,662 shares of common stock directly, alongside the new unvested RSUs and options.
InfuSystem Holdings director Kenneth D. Eichenbaum reported a new stock option grant tied to the company’s common stock. He received options covering 24,890 shares at an exercise price of $8.37 per share, recorded as a grant or award acquisition.
The option vests on May 12, 2027 and expires on May 12, 2036, giving him the right to buy InfuSystem common shares at the fixed exercise price once vested. Following these entries, he is shown holding 6,000 shares of common stock directly.
InfuSystem Holdings director Paul Andrew Gendron bought additional company stock in the open market. On this Form 4, he reports purchasing 5,000 shares of common stock in an open-market transaction at a weighted average price of $8.88 per share, increasing his direct holdings to 70,000 shares. A footnote explains the price reflects multiple trades on the transaction date and that full trade-by-trade pricing information is available upon request.
InfuSystem Holdings, Inc. President and CEO Carrie Lachance bought a net 3,000 shares of common stock in open-market purchases. She acquired 2,000 shares at $8.83 per share on May 8, 2026 and 1,000 shares at $8.46 per share on May 11, 2026.
After these transactions, she directly holds 238,123 shares of InfuSystem common stock. This total includes an additional 2,949 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings, Inc. Executive VP and CFO Barry G. Steele reported buying 7,000 shares of common stock in an open-market purchase at a weighted average price of $8.707 per share. Following this transaction, he directly holds 96,590 common shares, including 1,590 shares recently acquired through the Company’s Employee Stock Purchase Plan.
InfuSystem Holdings executive Barry G. Steele, Executive VP and CFO, bought 2,064 shares of common stock in open-market purchases at a weighted average price of $9.16 per share. A footnote notes the total holdings also reflect 1,359 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings (INFU) insider transaction: EVP-Chief HR Officer Jerod Funke reported RSU settlement on October 9, 2025. Restricted stock units converted into common stock on a one-for-one basis, resulting in 12,500 shares acquired at $0 per share via code “M”. To cover taxes, the issuer withheld 3,669 shares at $9.61 under code “F”.
After these transactions, Funke directly owned 18,662 shares of InfuSystem common stock.